Table 3 Sample characteristics
|  | Study 1 (acute treatment, baseline) (n = 41) | Study 2 (follow-up care) (n = 34) |
|---|---|---|
Gender (n, %) | ||
 male | 17 (41.5) | 22 (64.7) |
 female | 24 (58.5) | 12 (35.3) |
 diverse | 0 (0.0) | 0 (0.0) |
Age (M, SD) | 6.93 (2.27) | 7.94 (2.28) |
Diagnosis (n, %) | ||
 Leukaemia | 20 (48.8) | 11 (32.4) |
 Lymphoma | 2 (4.9) | 2 (5.9) |
 Tumour of the central nervous system | 11 (26.8) | 8 (23.5) |
 Other solid tumoura | 8 (19.5) | 11 (32.4) |
 Langerhans cell histiocytosis | 0 (0.0) | 2 (5.9) |
Time since diagnosis in months (M, SD) | 8.03 (16.93) | 56.13 (24.88) |
Treatment modality (n, %—multiple responses possible) | ||
 Chemotherapy | 36 (90.0) | 28 (82.4) |
 Radiotherapy | 5 (12.5) | 4 (11.8) |
 Surgical measures | 14 (35.0) | 14 (41.2) |
 Haematopoietic stem cell transplant | 0 (0.0) | 0 (0.0) |
 Otherb | 0 (0.0) | 2 (5.9) |